• Based on the HNV study (NCT02243150) results, the G1T28 AUC is slightly lower than expected in the current study
• The lower G1T28 AUC may be an artifact of sampling differences between the studies and the rapid distribution of G1T28 after the end of infusion
• The carboplatin and etoposide PK parameters are within the expected range, indicating that there are no drug-drug interactions • There was no evidence of a pharmacokinetic drug-drug interaction between G1T28 and carboplatin or etoposide
• This novel approach, allowing the administration of chemotherapy with preservation of hematopoietic and immune system function, could potentially improve treatment outcomes for patients with CDK4/6-independent tumors ABSTRACT #CT151
• Chemotherapy-induced toxicity to the bone marrow and immune system is a significant acute and long-term consequence of chemotherapy
• G1T28 is a highly potent and selective CDK4/6 inhibitor (CDK4/6i) in development to reduce chemotherapy-induced myelosuppression and preserve immune system function in patients with CDK4/6-independent cancers such as SCLC
• Hematopoietic stem and progenitor cells (HSPC) are dependent upon CDK4/6 for proliferation, and preclinical models demonstrated that transient G1T28-induced G1 cell cycle arrest renders them resistant to chemotherapy cytotoxicity, allowing faster hematopoietic recovery, preservation of long-term function, and enhancement of chemotherapy anti-tumor activity
• In a Phase 1a healthy normal volunteer (HNV) study (NCT02243150): 
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* As of data cutoff (01Apr2016), the first 6 enrolled patients were evaluable for safety and response
Abbreviations: ECOG, Eastern Cooperative Oncology Group.
*Toxicities were graded using NCI CTCAE (Common Terminology Criteria for Adverse Events), Version 4.03. All treatment-related adverse events were attributed to chemotherapy and none were attributed to G1T28. A.
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• 100% confirmed response rate
• The first six enrolled patients have completed treatment  Five patients received six cycles and one patient received four cycles
• All six patients are in the survival follow-up phase to determine progression free survival (PFS) and overall survival (OS)
• Two patients in the survival follow-up phase developed asymptomatic brain metastases FIGURE 2. BEST CHANGE IN TUMOR SIZE FROM BASELINE
